Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for Aytu Biopharma (AYTU) over the last 6 years, with Q4 2020 value amounting to $475680.0.

  • Aytu Biopharma's Current Deferred Revenue changed N/A to $475680.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $475680.0, marking a year-over-year change of. This contributed to the annual value of $339336.0 for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q4 2020, Aytu Biopharma's Current Deferred Revenue is $475680.0.
  • Aytu Biopharma's Current Deferred Revenue's 5-year high stood at $475680.0 during Q4 2020, with a 5-year trough of $1450.0 in Q2 2018.
  • Moreover, its 4-year median value for Current Deferred Revenue was $13990.0 (2018), whereas its average is $145070.9.
  • Per our database at Business Quant, Aytu Biopharma's Current Deferred Revenue skyrocketed by 39700.17% in 2016 and then crashed by 9843.36% in 2017.
  • Aytu Biopharma's Current Deferred Revenue (Quarter) stood at $426000.0 in 2016, then tumbled by 98.88% to $4787.0 in 2017, then skyrocketed by 192.25% to $13990.0 in 2018, then soared by 3300.14% to $475680.0 in 2020.
  • Its Current Deferred Revenue stands at $475680.0 for Q4 2020, versus $232576.0 for Q3 2020 and $339336.0 for Q2 2020.